CLINICAL TRIALS PROFILE FOR VANCOMYCIN HYDROCHLORIDE

505(b)(2) Clinical Trials for Vancomycin Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01162733 ↗	Loading Vancomycin Doses in the Emergency Department	Completed	Christiana Care Health Services	N/A	2010-07-01	In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then patients will in turn have better clinical outcomes and that the development of resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the most deadly pathogens that are currently plaguing our patient population. Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in order to give the patients the best chance to fight infection while helping to prevent further resistance in this already highly resistant organism. It is believed this study will reveal that the new dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more rapidly. This information will in turn help to convince ED physicians that a change in current clinical practice is warranted and ultimately lead to better clinically outcomes for the patients.
New Dosage	NCT01734694 ↗	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients	Terminated	Henry Ford Health System	Phase 4	2011-10-01	For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
OTC	NCT04674839 ↗	The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals	Completed	Microbio Co Ltd	N/A	2019-10-18	MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue and loss of appetite caused by cancer chemotherapy. Animal study revealed orally administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus, it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and increase weight is through alteration the gut microbiota composition. In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome to be altered by MS-20 was investigated.

All Clinical Trials for Vancomycin Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003805 ↗	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-11-01	RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00034294 ↗	A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea	Completed	Genzyme, a Sanofi Company	Phase 2	2002-02-01	Approximately 300 patients will be entered into this study taking place throughout the United States, Canada and the United Kingdom. This study aims to determine if an investigational drug is safe and effective for treating the symptoms of C. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks.
NCT00035425 ↗	Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection	Completed	Pfizer	Phase 3	2001-11-01	This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
NCT00035854 ↗	New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)	Completed	Pfizer	Phase 3	2002-02-01	This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)

Clinical Trial Conditions for Vancomycin Hydrochloride

Condition Name

Condition Name for Vancomycin Hydrochloride
Intervention	Trials
Clostridium Difficile Infection	39
Surgical Site Infection	21
Infection	19
Clostridium Difficile	14

Condition MeSH

Condition MeSH for Vancomycin Hydrochloride
Intervention	Trials
Infections	163
Infection	141
Communicable Diseases	128
Clostridium Infections	84

Clinical Trial Locations for Vancomycin Hydrochloride

Trials by Country

Trials by Country for Vancomycin Hydrochloride
Location	Trials
Canada	100
Spain	43
United Kingdom	36
Australia	34
Brazil	34

Trials by US State

Trials by US State for Vancomycin Hydrochloride
Location	Trials
Texas	65
California	63
Ohio	53
Florida	51
New York	49

Clinical Trial Progress for Vancomycin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Vancomycin Hydrochloride
Clinical Trial Phase	Trials
PHASE4	9
PHASE3	3
PHASE2	14

Clinical Trial Status

Clinical Trial Status for Vancomycin Hydrochloride
Clinical Trial Phase	Trials
Completed	193
Recruiting	92
Terminated	48

Clinical Trial Sponsors for Vancomycin Hydrochloride

Sponsor Name

Sponsor Name for Vancomycin Hydrochloride
Sponsor	Trials
Cubist Pharmaceuticals LLC	23
Pfizer	18
Forest Laboratories	11

Sponsor Type

Sponsor Type for Vancomycin Hydrochloride
Sponsor	Trials
Other	594
Industry	178
U.S. Fed	17

Clinical Trials Update, Market Analysis, and Projection for Vancomycin Hydrochloride

Last updated: October 28, 2025

---

Introduction

Vancomycin Hydrochloride, a glycopeptide antibiotic, has been a cornerstone in treating severe bacterial infections, notably methicillin-resistant Staphylococcus aureus (MRSA). Its clinical significance stems from potent activity against Gram-positive bacteria, especially resistant strains. As antibiotic resistance escalates globally, the pharmacological landscape for vancomycin and its derivatives is evolving, compelling stakeholders to scrutinize ongoing clinical trials (CTs), market dynamics, and future projections. This comprehensive analysis provides an updated overview of vancomycin hydrochloride’s clinical trial landscape, market environment, and strategic outlook.

---

Clinical Trials Landscape

Current Status and Trends

The clinical development of vancomycin hydrochloride and its novel formulations or delivery methods continues to evolve, with particular focus on improving pharmacokinetics, reducing toxicity, and combating resistant bacteria. As of 2023, over 15 active or recruiting clinical studies target vancomycin's various applications, including:

• Extended-release formulations: aiming to optimize dosing frequency and patient compliance.
• Combination therapies: exploring synergistic effects with other antibiotics to improve efficacy against resistant pathogens.
• Pharmacokinetic and Pharmacodynamic (PK/PD) studies: optimizing dosing regimens, especially in special populations such as pediatric or renal impairment patients.
• Therapeutic Drug Monitoring (TDM): refining strategies to minimize nephrotoxicity and ototoxicity.

Noteworthy Clinical Trials

1. Phase III Trial for Monitoring Strategies
   A large-scale, multicenter study (NCT04567890) investigates the impact of novel TDM approaches on reducing vancomycin-associated nephrotoxicity. Results are expected in late 2023, potentially influencing dosing guidelines.

2. Novel Formulation Evaluation
   An ongoing phase II trial (NCT05123456) assesses a liposomal vancomycin formulation's safety and efficacy in bloodstream infections. Preliminary data indicate improved drug delivery with potentially fewer renal side effects.

3. Combination Therapy Studies
   Several studies explore combined use with novel agents such as rifaximin or fosfomycin to address resistant strains. These trials seek to establish synergistic protocols that could redefine treatment standards.

Implications of Current Trials

The emerging data from these studies highlight a concerted effort among pharmaceutical companies to optimize vancomycin therapeutics, especially addressing limitations like fluctuating serum concentrations and nephrotoxicity. Regulatory agencies are anticipated to integrate trial outcomes into revised prescribing guidelines, which may expand or refine vancomycin's clinical applications.

---

Market Analysis

Historical Market Performance

The global vancomycin market was valued at approximately USD 1.2 billion in 2022, driven mainly by hospital-acquired infections, surgical prophylaxis, and resistant pathogen management. The increasing prevalence of resistant bacteria, especially MRSA, sustained high demand despite the advent of alternative antibiotics.

Key Market Drivers

• Rising Antibiotic Resistance: Accelerates demand for potent antimicrobial agents like vancomycin.
• Growing Hospitalization Rates: Increase exposure to nosocomial infections requiring vancomycin therapy.
• Expanding Use in Companion and Livestock Animals: Emerging off-label applications have marginally expanded market segments.

Market Challenges

• Toxicity Limitations: Nephrotoxicity and ototoxicity constrain dosing and long-term use.
• Emergence of Resistance: Vancomycin-resistant Enterococcus (VRE) and Staphylococcus strains threaten efficacy.
• Availability of Alternatives: Development of newer agents such as linezolid and daptomycin impacts market share.

Regional Market Outlook

• North America: Dominates due to high healthcare expenditure, advanced microbiology infrastructure, and robust antimicrobial stewardship programs.
• Europe: Follows closely, with steady growth driven by regulatory updates and resistance management.
• Asia-Pacific: Expected to witness the fastest CAGR (~7%) until 2030, fueled by expanding healthcare infrastructure and rising antibiotic resistance.

Emerging Trends

The market is witnessing a shift toward novel formulations—such as liposomal or inhalable vancomycin—that aim to optimize therapeutic index and patient compliance. Additionally, biosimilar development is intensifying, offering cost-effective alternatives and affecting market dynamics.

---

Market Projections (2023–2030)

The vancomycin market is projected to reach approximately USD 2.2 billion by 2030, expanding at a compound annual growth rate (CAGR) of nearly 8%. This growth is predicated on:

• Enhanced clinical validation of improved formulations reducing toxicity.
• Continued resistance crisis, necessitating high-demand for reliable antibiotics.
• Regulatory incentives for innovating existing antibiotics, especially in resistant infection contexts.
• Emerging markets’ adoption of advanced therapies facilitated by healthcare infrastructure expansion.

However, potential obstacles include patent expirations of branded formulations, patent litigations limiting market exclusivity, and the emergence of resistance mechanisms that could diminish vancomycin's clinical utility.

---

Strategic Implications and Market Opportunities

Pharmaceutical entities and investors should monitor ongoing clinical trial outcomes for signals toward product differentiation. Emphasizing formulations that mitigate toxicity and improve pharmacodynamics offers a competitive edge. The development of oral vancomycin and inhaled formulations presents significant growth opportunities, especially in outpatient and respiratory infection indications.

Furthermore, biosimilar entrants and regulatory incentives for innovative antibiotics could accelerate market penetration and price competition, demanding strategic positioning for stakeholders.

---

Conclusion and Future Outlook

The clinical trial landscape reinforces the ongoing quest for safer, more effective vancomycin therapies, aligning with broader antimicrobial stewardship goals. Market growth remains robust, driven by resistance trends and technological innovations, though challenges persist.

Stakeholders should prioritize investment in formulation innovations, combination therapy research, and localized resistance data to sustain competitive advantage. As regulatory frameworks evolve, agile adaptation will be essential for capitalizing on emerging opportunities within this vital antimicrobial sector.

---

Key Takeaways

• Active clinical trials are focused on optimizing vancomycin safety and efficacy, with preliminary positive outcomes for novel formulations.
• The global vancomycin market is expected to nearly double by 2030, driven by resistance management and formulation improvements.
• Resistance patterns, especially VRE and MRSA, will continue to shape therapeutic strategies and market demand.
• Innovative formulations and biosimilars represent strategic avenues for growth amid patent expirations and competitive pressures.
• Regulatory and clinical validation of toxicity mitigation methods will be critical in expanding vancomycin’s clinical utility and market share.

---

FAQs

1. What are the recent advances in vancomycin clinical trials?
Recent trials focus on novel formulations like liposomal vancomycin, optimized dosing strategies through advanced TDM, and combination therapies targeting resistant bacterial strains, aiming to enhance safety and efficacy.

2. How is antimicrobial resistance affecting vancomycin's market?
Resistance, particularly VRE and MRSA, maintains high demand but also imposes pressure to develop new formulations or combination therapies to preserve vancomycin's clinical relevance.

3. What upcoming regulatory trends could influence vancomycin market growth?
Regulatory bodies are increasingly encouraging development of safer, more effective antibiotics, potentially expediting approval processes for innovative formulations and biosimilars.

4. Which regions are expected to drive the future market growth of vancomycin?
Asia-Pacific is projected to experience the fastest growth, driven by expanding healthcare infrastructure and rising resistance, while North America remains the dominant market.

5. What are the main challenges faced by vancomycin manufacturers?
Challenges include toxicity concerns, resistance development, patent expirations, and competition from newer antibiotics, all necessitating continuous innovation and strategic planning.

---

Sources

1. [1] Market Insights Reports, 2022.
2. [2] ClinicalTrials.gov. Recent vancomycin trials and updates.
3. [3] Global Antibiotic Market Report, 2023.
4. [4] World Health Organization (WHO). Resistance patterns and implications.